← Human Trials & Peer-Reviewed Studies
Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels
Plain-language guide to PMID 18028171 (2007): clinical trial study of Parathyroid Hormone (PTH 1-84) in 71 men, hyperparathyroidism.
Key Facts
- PMID
- 18028171
- Journal
- Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
- Year
- 2007
- Study type
- Clinical Trial
- Authors
- Kokuho T et al. (13 authors)
- DOI
- 10.1111/j.1744-9987.2007.00524.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism in this clinical trial publication.
The researchers also conducted stratified analysis based on patient background and multivariate analysis to determine the factors affecting these parameters.
Why It Was Studied
However, it remains unknown whether sevelamer restores bone metabolism in hemodialysis patients with low bone turnover osteodystrophy and hypoparathyroidism.
The researchers investigated the changes in serum intact parathyroid hormone (iPTH) and bone metabolic marker levels after replacing calcium carbonate with sevelamer in these patients.
Who Took Part
The abstract describes 71 men taking part.
The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.
During sevelamer replacement therapy, serum calcium and phosphate concentrations, and the calcium phosphate product were measured at 0, 1, 3, and 6 months.
How the Study Was Run
Serum iPTH, bone alkaline phosphatase and osteocalcin concentrations were measured at 0 and 6 months.
What Was Measured
The researchers investigated the changes in serum intact parathyroid hormone (iPTH) and bone metabolic marker levels after replacing calcium carbonate with sevelamer in these patients.
The subject headings attached to it are Biomarkers, Bone and Bones, Calcium, Calcium Phosphates, Hyperphosphatemia, Parathyroid Hormone and Phosphates.
What This Means in Plain Language
This is a clinical trial of Parathyroid Hormone (PTH 1-84) in 71 men in people with hyperparathyroidism.
The publication is from 2007 (Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy), a journal based in Australia.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.